DWA
ORMP icon

Dorsey Wright & Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

Dorsey Wright & Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,518
Closed -$121K – 317
2021
Q3 		$121K Buy
5,518
+432
+8% +$7.36K 0.03% 126
2021
Q2 		$68K Hold
5,086
– – 0.01% 147
2021
Q1 		$51.7K Buy
+5,086
New +$41.7K 0.61% 44

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Dorsey Wright & Associates's ORMP Position: Q4 2021 in Review

Dorsey Wright & Associates sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 5,518 shares — an estimated $121K sold.

Dorsey Wright & Associates first reported a position in ORMP in Q1 2021 and held it in 3 quarters. The position peaked at $121K in Q3 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • Dorsey Wright & Associates reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 5,518 Oramed Pharmaceuticals shares in Q4 2021, an estimated $121K.
  • Dorsey Wright & Associates first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Dorsey Wright & Associates's Oramed Pharmaceuticals position peaked at $121K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Dorsey Wright & Associates's 13F filing for Q4 2021, filed 27 Jan 2022.